ther 1.5 hr, poured into H_2O , and extracted twice with Et_2O . The aq layer was acidified with aq HCl and the precipitated solid collected and dried. Recrystallization from H_2O -EtOH gave 21 g of the product (75%), mp 117-118°. Anal. (C₁₄- $H_{16}O_5$) C, H.

5,6-Dimethoxyindan-2-one (VII, $\mathbf{R} = \mathbf{H}$).—VII ($\mathbf{R} = CO_2 Et$) (10 g) was heated at 100° with 20% H₂SO₄ (70 ml) for 2 hr. The solution was extracted with EtOAc and the organic phase washed with H₂O, dried, and concentrated *in vacuo*. The dark red residue was filtered through a Florisil column in C₆H₆, when removal of solvent and recrystallization from EtOH gave 6 g (83%) of product, mp 137–139°. Anal. (C₁₁H₁₂O₃) C, H.

Spiro(5,6-dimethoxyindan)-2,5'-hydantoin (VIII).--5,6-Dimethoxyindan-2-one (7 g), NaCN (3.6 g), and $(NH_4)_2CO_3$ (16.7 g) were heated in 40% EtOH (300 ml) for 3 hr at 60°. The temperature was maintained at 100° until unreacted $(NH_4)_2CO_3$ was removed, and allowed to cool when 4 g (42% yield) of the hydantoin, mp 298° dec was obtained. Anal. (C₁₃H₁₄N₂O₄) C, H, N.

2-Amino-5,6-dimethoxyindan-2-carboxylic Acid (II, R =Me).—A mixture of the hydantoin (VIII) (3.4 g) and $Ba(OH)_2$ (6 g) in H_2O (50 ml) was refluxed for 24 hr, the hot solution filtered, and the filtrate boiled with $(NH_4)_2CO_3$ (2 g). The filtrate was concentrated in vacuo until crystallization occurred, and MeOH (100 ml) was added, when $2.5~{\rm g}~(82\%~{\rm yield})$ of the product, mp 299-300° dec was obtained. Anal. (C12H15NO4)C, H, N. 2-Amino-5,6-dihydroxyindan-2-carboxylic Acid Hydrobromide (II, $\mathbf{R} = \mathbf{H}$).—The amino acid (II, $\mathbf{R} = \mathbf{M}e$) (1 g) in CH_2Cl_2 (30 ml) was treated at -70° with a solution of BBr₃ (0.5 g) in CH_2Cl_2 (10 ml) and cooled to -70° . The reaction mixture was allowed to reach room temp overnight, H_2O (1 ml) added, and the dark brown solid filtered off. Treatment of the solid with charcoal in hot EtOH gave on concentration in vacuo, 0.7 g (57%)yield) of the product, mp 250-254°. An analytical sample was recrystallized from EtOH-Et₂O, mp 260° dec. Anal. (C₁₀H₁₂-BrNO₄)C, H, N, Br.

Synthesis and Pharmacology of a Series of Substituted 2-Aminomethylpyrroles¹


STEPHEN RAINES AND CSABA A. KOVACS

The National Drug Company, Research Laboratories, Division of Richardson-Merrell Inc., Philadelphia, Pennsylvania 19144

Received April 20, 1970


In a search for compounds which have an effect on the CNS, it was found that certain substituted 2-aminomethylpyrroles demonstrated a significant degree of depressant activity coupled with a relatively high LD_{50} . This note reports the compounds prepared in this area, in addition to their biological activity.

Chemistry.—The preparation of the necessary starting materials utilizing a Mannich reaction on pyrrole has been reported.² These substituted aminomethylpyrroles (**1a-d**) were treated with compounds having electrophilic groups (acid chlorides, acid anhydrides, isocyanates, isothiocyanates, etc.) giving in all cases the expected products (Table I).



All reprint requests should be sent to Mr. Frank P. Palopoli; Wm. S. Merrell Company; Cincinnati, Ohio 45215.

The LAH reduction of 20 resulted in the formation of the known compound 2^3 confirming the assigned structure. The direction of ring opening of styrene oxide when combined with 1a was established by a LAH reduction of 9, while the amide 7 using the same reducing agent was converted into the tertiary amine 19.



Pharmacology.—A number of compounds prepared demonstrated a significant degree of CNS depressant activity (see Table I) in dose range studies in mice. The MLD (2000 mg/kg, po) and the minimal symptomatic dose (31 mg/kg, po) were determined for **20**. Phenobarbital when employed in dose range studies was found to have a minimal symptomatic dose of 15 mg/kg po.

In addition, the compounds reported in this paper were administered orally and screened for antihypertensive activity in renal hypertensive rats,⁴ antiinflammatory activity in the carrageenin abscess test in rats⁵ and analgetic activity in the phenylquinone-induced writhing test in mice.⁶ There was no significant activity noted in these areas.

Experimental Section

All compounds had ir spectra in agreement with their assigned structures and analyzed for C, H, and N within ± 0.4 per cent of their theoretical values.

(3) W. Herz, K. Dittmer, and S. J. Cristol, J. Amer. Chem. Soc., 69, 1698 (1947).

(4) A. Grollman, Proc. Soc. Exp. Biol. Med., 57, 102 (1944).

(5) S. Goldstein and M. Schnall, Arch. Int. Pharmacodyn., 144, 269 (1963).

(6) L. C. Hendershot and J. Forsaith, J. Pharmacol. Exp. Ther., 125, 237 (1959).

⁽²⁾ S. Raines and C. A. Kovacs, J. Heterocycl. Chem., 7, 223 (1970).



					R' R						
No.	R	R'	R″	Pyrrole compd		Method	$Mp_{c} = \frac{2C}{2C}$	Recrystn solvent	√i yield	Formula	Activ- ity ^h
з	CH2CO	H	CH_3	la	(CH ₃ CO) ₂ O	D	74-76	EteO	56	$C_3H_{12}N_2O$	+ +
.4	CeHsCO	H	CHa	la	C ₆ H ₅ COC	A	87-89	Et ₂ O	-59 -59	C13H12N2O	++
5	p-ClC ₆ H ₄ CO	Н	CHs	la	p-ClC ₆ H ₄ COCl	A	146-147	EtOH	22	CisHisCINcO	
6	p-FC ₆ H ₄ CO	Н	CH_3	la	p-FCeH4COC1		141-143	EtOH	49	C ₁₃ H ₁₃ FN ₂ O	
7	3.4.5-(CH _{\$} O) _{\$} C ₆ H ₂ CO	Н	CH_3	1a	3,4,5-(CH ₃ O) ₃ C ₆ H ₂ COC]	3	122 - 124	EtOH	76	$C_{16}H_{20}N_2O_4$	÷-
8	C6H4CH2CO	Н	CH_3	1a	C ₆ H ₅ CH ₂ COCl		87-89	EtOH	29	C14H15N2O	
9	$(C_6H_3)(CH_3CO_2)CHCO$	Н	С.Нз	1a	(C ₈ H ₃)(CH ₂ CO ₂)CHCOCI	.\	117119	Et ₂ O- cyclohexane	77	$C_{10}H_{28}N_2O_7$	
10	C₂H₅OCO	H	CH_2	la	C2H5OCOCI	Δ.	Oil		31	$C_{9}H_{14}N_{2}O_{2}$	
11	p-CH ₃ C ₆ H ₄ SO ₂	Н	CH_3	la	p-CH5C6H48O2Cl	.1	8688	EtOH	61	$C_{13}H_{16}N_2O_2S$	-
12	C ₆ H ₅ NHCO	Н	CH_3	1a	C ₆ H ₄ NCO	13	$79 \cdot 81$	Et ₂ O petr ether	48	$C_{13}H_{15}N_5O$	
13	CH3(CH2)3NHCO	Н	CHa	la	$CH_{\delta}(CH_{2})_{3}NCO$	B	4345	Et ₂ O cyclohexane	79	$C_{H}H_{10}N_{\rm E}O$	· •
14	S-NHCO	Н	CH_3	la	S-NCO	В	105 - 107	Et:O	67	$C_{12}H_{\rm M}N_{\rm F}O$	
15	C_6H_5NHCS	Н	CHs	la	C ₆ H ₅ NCS	В	132-134		86	$C_{13}H_{15}N_2S$	
16	$CH_3(CH_2)_3NHCS$	H	CH_8	1a	$CH_3(CH_2)/NCS$	В	54-55	Et ₂ O	51	C_1 : H \sim N $_3$ S	
								petr ether			
17	H ₂ NCOCH ₂ CH ₂	Н	CHa	la	CH ₂ =CHCONH ₂ O	C	123-125	EtOH	55	$C_{\rm e}H_{\rm E}N_{\rm S}O$	-4-
18	$C_8H_5CH(OH)CH_2$	Н	CH_3	la	C ₆ H ₄ CHCH ₂	E. F	72-74	Cyclohexane	1-20 2-67	CitHisN ₂ Ö	
19	$3.45 - (CH_{\$}O)_{\$}C_{6}H_{2}CH_{2}$	H	CH_3	la		Е	88-90	EtOH	56	$C_{16}H_{22}N_2O_N$	•
20	CH₃CO	Н	C_2H_3	115	$(CH_3CO)_2O$	i)	67-69		75	$C_{2}H_{14}N_{2}O$	· • · · •
21	C ₆ H ₅ CO	11	C_2H_5	15	C ₆ H ₅ COCl	А	58-60	Et ₂ O cyclohexane	26	$C_{14}H_{10}N_{2}O$	
22	C ₆ H ₅ NHCO	Н	C_2H_5	11,	C ₆ H ₅ NCO	В	$87 \cdot 89$	Et ₂ O	65	$C_{14}H_{17}N_{3}O$	
23	C ₆ H ₅ NHC8	Н	C_2H_5	1b	C ₆ H ₅ NCS	В	96-98	Petr ether	100	$C_{14}H_{07}N_{18}S$	÷
24	p-ClC ₆ H ₄ CO	H	$CH_3(CH_2)_2$	1e	p-ClC ₆ H ₄ COCl	A	59-61	Et ₂ O- petr ether	39	$C_{17}H_{17}C1N_{2}O$	
25	C_6H_5NHCO	Н	$-CH_3(CH_2)_2$	1 e	C ₆ H ₅ NCO	В	123 - 125		78	$C_{15}H_{10}N_{2}O$	• •••
26	p-ClC6H₄CO	CH_3	CH_8	\mathbf{ld}	p-ClC6H4COCl	A	55~57	Cyclohexane	7.1	$C_{14}H_{15}ClN_2O$	
27	p-CH ₃ C ₆ H ₄ SO ₂	CH_3	CH3		p-CH ₃ C ₆ H ₄ SO ₂ C	Δ	117 - 119	$-(CH_3OCH_2)_2$	77	$C_{14}H_{18}N_2O_2S$	
28	CeH5NHCO	CH_8	CH_8		C ₆ H ₅ NCO	В	129 - 131	EtOH~Et ₂ O	57	$C_{14}H_{17}N_2O$	
. 1371	•1	1	1 1 •	. 1	1. 1 .1 .1 .1 .1	•					

" Where oils or gums were obtained employing the listed methods, crystallization was induced by trituration with an appropriate organic solvent (usually petroleum ether, cyclohexane or ether). ^b CNS depressant activity (standard mouse dose range study): + = activity below 500 mg/kg po; ++ = activity below 250 mg/kg; - = inactive.

Method A.— To an ice-cooled and stirred solution of the pyrrole compd (0.1 mole), Et_3N (0.3 mole), and C_6H_6 (300 ml), a solution of acid chloride (0.1 mole) in C_6H_6 (100 ml) was added dropwise over a 2-hr period. The reaction mixture was stirred for 6 hr and let stand overnight. The Et₃N·HCl formed was extracted from the C_6H_6 solution with H_2O (200 ml). The organic layer was dried (Na₂SO₄) and filtered, followed by concentration under reduced pressure.

Method B.--A mixture of the pyrrole compd (0.05 mole) and the appropriate isocyanate (0.05 mole) or isothiocyanate (0.05 mole) in \hat{C}_6H_6 (200 ml) was permitted to stand at room temp for 16 hr. The solvents were removed under reduced pressure.

Method C. A mixture of the pyrrole compd (0.1 mole) and the α,β -unsaturated compd (0.1 mole) and $\dot{C}_{6}H_{6}$ (300 ml) was stirred and refluxed for 10 hr. The reaction mixture was permitted to stand 16 hr at room temp during this period. Compd 17 was deposited while 18 was obtained as an oil after removing the solvent and purified by passing through a neutral silica column using EtOH as a solvent.

Method D .-- To a cooled and stirred solution of the pyrrole compd (0.1 mole) dissolved in C_6H_6 (300 ml) under N_2 , a solution of anhydride (0.1 mole) dissolved in C₆H₆ (200 ml) was added dropwise. After the addition was complete, the reaction was stirred for 12 hr, followed by extraction with two 100-ml portions of 10% aq NaOH and 100 ml of H₂O. The C₆H₆ layer was dried (Na₂SO₄), filtered, and concd under reduced pressure.

Method E .-- To a cooled and stirred shurry of LAH (4 g) in THF (400 ml), a solution of the pyrrole compd (0.004 mole) dissolved in THF (200 ml) was added dropwise. After the addition was complete, the reaction mixture was refluxed for 5 hr. While cooling in an ice bath, the excess LAH was decomposed by the dropwise addition of a 10% NaOH solution (25 ml) and a satd Na₂SO₄ solution (25 ml). The reaction mixture was permitted to stir for 30 min followed by the addition of solid Na₂- SO₄ (15 g). The reaction mixture was filtered and the filter cake washed several times with hot THF. The filtrate was dried (Na₂SO₄), filtered, and concd under reduced pressure.

Method F.—A solution of the pyrrole compd (0.1 mole), styrene oxide (0.1 mole) dissolved in Et₂O (200 ml) was permitted to stand for 8 days at room temp. The Et₂O was evaporated and the resulting oil (18) heated on the steam bath for 2 hr.

A New Group of Anorexigenic Compounds

KURT FRETER,* MANFRED GÖTZ, AND JAMES T. OLIVER

Pharma-Research Canada Ltd., Montreal 730, P. Q., Canada

Received April 20, 1970

The therapy of obesity is either based on reducing diets or on drugs which diminish the desire for food intake in excess of the energy expenditure-or most successfully—a combination of both. Anorexigenic agents presently in use are phenethylamine derivatives comprising the structural elements aryl-C-C-N¹⁻³ which show varying degrees of stimulation.

^{*} To whom correspondence should be addressed.

⁽¹⁾ A. Engelhardt, Acta Neuroveg., 24, 647 (1963).

⁽²⁾ D. Lorenz, Mitt. Deut. Pharm. Ges. Pharm. Ges. DDR, 36, 269 (1966).
(3) G. Ehrhart and H. Rushig, "Arzneimittel," Verlag Chemie, Weinheim, 1968, p 139.